Parameter | iPFS (months) | HR | 95%CI | P |
|---|
Neurologic symptoms | | | | 0.002 |
No | 30.7 | 1.000 | | |
Yes | 17.6 | 2.025 | 1.238-3.313 | |
BM size, Dmax(cm) | | | | 0.213 |
≤ 3 | 27.9 | 1.000 | | |
> 3 | 18.2 | 1.458 | 0.806–2.639 | |
RPA class | | | | 0.055 |
1 | 33.5 | 1.000 | | |
2 | 19.7 | 1.710 | 0.989–2.957 | |
TT after BMs | | | | 0.007 |
Yes | 26.5 | 1.000 | | |
No | 20.3 | 2.073 | 1.221–3.520 | |
- BMs brain metastases, EMs extracranial metastases, GPA graded prognostic assessment, HR hazard ratio, iPFS intracranial progression-free survival, LINAC-SRS stereotactic radiotherapy using linear accelerators, KPS Kanofsky Performance Scale, RPA recursive partitioning analysis, SCC squamous cell carcinoma, TT targeted therapy, WBRT whole-brain radiotherapy, WBRT + RTB whole-brain radiotherapy plus radiotherapy boost
